Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of atropine sulfate injection [2] Group 1 - The approval is a significant regulatory milestone for the company, indicating progress in its product development and compliance with national standards [2] - Atropine sulfate injection is likely to enhance the company's product portfolio and potentially increase market competitiveness [2]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its raw material drug, Levonorgestrel, has passed the WHO prequalification, allowing it to be included in procurement by international organizations and public institutions [1] Group 1 - The company announced that its Levonorgestrel product is now recognized by the WHO, expanding its market potential [1] - The company's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Atropine Sulfate Injection, which includes the addition of a new specification of 1ml: 0.5mg [1] - The approval also pertains to the consistency evaluation of the quality and efficacy of the generic drug [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Atropine Sulfate Injection [1] Group 1 - Atropine Sulfate Injection is primarily used for various visceral spasms, such as gastrointestinal colic and bladder irritability [1] - The drug is also indicated for pre-anesthesia medication, severe sweating and salivation, and bradyarrhythmias caused by excessive vagal nerve stimulation [1] - Additionally, it can be used for shock treatment and to counteract poisoning from organophosphate esters [1]